November 12, 2008

Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter

DOYLESTOWN, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation announced today that the last subject in the Phase IIb Study is scheduled to complete treatment on November 25, 2008. This will effectively move the study to the final stage of data collection, evaluation and study conclusions. The Company, after collecting all the patient information from 21 Study centers and conferring with its panel of experts on the data, will draft and report study conclusions, as soon they are available.

The Phase IIb study is designed to evaluate the safety and efficacy of QR-333, a unique topical formulation designed to offer physicians and patients an effective, easy to administer, safe treatment for diabetic peripheral neuropathy with little to no side effects. To date there is no fully effective treatment for diabetic neuropathy. Current treatment options are limited to products such as NSAIDs, analgesics, anticonvulsants, antidepressants, etc., which are often not well tolerated by patients.

The Company believes that a safe and efficacious topical product, if approved by the FDA, could be a "first line" treatment for diabetic peripheral neuropathy and possibly could develop a significant market position in a growing therapeutic category currently dominated by systemic therapies.

Currently in the United States, there are approximately 20,000,000 people with diabetes. Of this population, nearly one half has or will develop symptoms of peripheral neuropathy. Diabetic neuropathy is among the most common complications of diabetes, resulting in pain and numbness, which affects the patient's sleep, functioning and well being. The pain is often accompanied by unpleasant sensations of buzzing, burning or jolting.

The Phase IIb trial will evaluate the safety and efficacy of QR-333, applied three times daily as compared to placebo-treated patients over 12 weeks. Efficacy will be determined by Symptom Assessment Scores; a Visual Analogy Scale (VAS); Quality of Life and Sleep Questionnaires. Safety will be determined by medical history; physical examination; vital signs, laboratory tests and nerve conduction studies.

   QR333 Investigation Chronology:    --  April 2003; Quigley receives first U.S. patent; "Method and       Composition for the Topical Treatment of Diabetic Neuropathy".    --  April 2003; Quigley announces safety and positive results from proof       of principal, efficacy and safety trial, "A multicenter, double blind       safety study of QR333 for the treatment of symptomatic diabetic       peripheral neuropathy", in France.    --  June 2005; Published results of proof of principal study in Journal of       Diabetes and Its Complications, "A multicenter, double blind safety       study of QR333 for the treatment of symptomatic diabetic peripheral       neuropathy A preliminary report".    --  Sept 2005; Quigley conducts Investigators meeting and prepares for       Pharmacokinetic Study-003 followed by Phase IIb Safety and Efficacy       Study-002 in humans in the U.S., pending issuance of IND number from       FDA.    --  April 2006; Quigley receives IND No. 67,168 from FDA.    --  August 2006; Quigley receives second U.S. patent; "Method for the       Topical Treatment of Small Fiber Neuropathies".    --  September 2006; Quigley reports positive data from Study-003, "SINGLE       CENTER, DOSE ESCALATING, SAFETY, TOLERABILITY, AND PHARMACOKINETICS       STUDY OF QR-333 IN SUBJECTS WITH DIABETIC PERIPHERAL NEUROPATHY"    --  December 2006; Quigley announces commencement of Study-002, "PHASE II       STUDY OF QR-333 FOR THE TREATMENT OF SYMPTOMATIC DIABETIC PERIPHERAL       NEUROPATHY".    --  August 2008; Quigley receives third U.S. patent; "Methods for the       Treatment of Peripheral Neural & Vascular Ailments".    About QR333:  

Concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder that can lead to numbness, skin ulcers, constant pain or extreme sensitivity to a stimulus.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will allow this Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation

The Quigley Corporation is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities and Quigley Pharma Inc. ( conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

   CONTACT:   Media                          Investor Relations   Karen Pineman                  Carl Hymans   G.S. Schwartz & Co.            G.S. Schwartz & Co.   212.725.4500                   212.725.4500   [email protected]          [email protected]  

Quigley Pharma Inc.

CONTACT: Media, Karen Pineman, [email protected], or Investors, CarlHymans, [email protected], both of G.S. Schwartz & Co., +1-212-725-4500,

Web Site: